Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00066469
Status:
COMPLETED
Last Update Posted:
2019-08-06
First Post:
2003-08-06
Brief Title:
Cyclophosphamide Rituximab and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Sponsor:
Childrens Oncology Group
Organization:
Childrens Oncology Group
Study Overview
Official Title:
Phase II Study of Cyclophosphamide Prednisone and Rituximab CPR in Children Adolescents and Young Adults With B-lymphocyte Antigen CD20 CD20 Positive Post-Transplant Lymphoproliferative Disease PTLD Following Solid Organ Transplantation SOT
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as cyclophosphamide prednisone and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells Combining cyclophosphamide and either prednisone or methylprednisolone with rituximab may be effective in treating lymphoproliferative disease following organ transplantation
PURPOSE Phase II trial to study the effectiveness of combining cyclophosphamide and either prednisone or methylprednisolone with rituximab in treating patients who have Epstein-Barr virus-positive lymphoproliferative disease following organ transplantation
PURPOSE Phase II trial to study the effectiveness of combining cyclophosphamide and either prednisone or methylprednisolone with rituximab in treating patients who have Epstein-Barr virus-positive lymphoproliferative disease following organ transplantation
Detailed Description:
OBJECTIVES
Determine the safety and toxicity of cyclophosphamide rituximab and prednisone or methylprednisolone in patients with CD20-positive and Epstein-Barr virus-positive post-transplant lymphoproliferative disease PTLD after solid organ transplantation
Determine the 2-year event-free survival defined as alive and in continuous complete remission with a functioning original allograft of patients treated with this regimen
Determine the response rate in patients treated with this regimen
Determine the PTLD gene expression profile by microarray analysis and fluorescent in situ hybridization in patients treated with this regimen
Determine the accrual rate of patients to this study
OUTLINE This is a multicenter study
Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5 During courses 1 and 2 only patients also receive rituximab IV over 2-5 hours on days 1 8 and 15 Treatment repeats every 21 days for up to 6 courses in the absence of disease progression a new primary or secondary malignancy or unrelated disease
After finishing study treatment patients are followed periodically for at least 5 years
PROJECTED ACCRUAL A total of 60 patients 50 with non-fulminant post-transplant lymphoproliferative disease PTLD and 10 fulminant PTLD will be accrued for this study within 25-3 years
Determine the safety and toxicity of cyclophosphamide rituximab and prednisone or methylprednisolone in patients with CD20-positive and Epstein-Barr virus-positive post-transplant lymphoproliferative disease PTLD after solid organ transplantation
Determine the 2-year event-free survival defined as alive and in continuous complete remission with a functioning original allograft of patients treated with this regimen
Determine the response rate in patients treated with this regimen
Determine the PTLD gene expression profile by microarray analysis and fluorescent in situ hybridization in patients treated with this regimen
Determine the accrual rate of patients to this study
OUTLINE This is a multicenter study
Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5 During courses 1 and 2 only patients also receive rituximab IV over 2-5 hours on days 1 8 and 15 Treatment repeats every 21 days for up to 6 courses in the absence of disease progression a new primary or secondary malignancy or unrelated disease
After finishing study treatment patients are followed periodically for at least 5 years
PROJECTED ACCRUAL A total of 60 patients 50 with non-fulminant post-transplant lymphoproliferative disease PTLD and 10 fulminant PTLD will be accrued for this study within 25-3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA098543 | NIH | NCI | httpsreporternihgovquickSearchU10CA098543 |
| CDR0000316241 | OTHER | None | None |
| COG-ANHL0221 | OTHER | None | None |
| NCI-2012-02544 | OTHER | None | None |